Indication

Neoplasm associated with von Hippel-Lindau disease

A neoplasm associated with von Hippel-Lindau disease refers to any of the benign or malignant tumors and cysts that arise in patients with von Hippel-Lindau disease, a rare autosomal dominant hereditary cancer predisposition syndrome. Read more about Neoplasm associated with von Hippel-Lindau disease

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Neoplasm associated with von Hippel-Lindau disease therapies.

Showing 1–1 of 1 drugs

WELIREG (belzutifan)

ANTINEOPLASTIC - HYPOXIA INDUCIBLE FACTOR (HIF) INHIBITORS·RENAL CELL CARCINOMA·+3
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with Neoplasm associated with von Hippel-Lindau disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Neoplasm associated with von Hippel-Lindau disease.

A neoplasm associated with von Hippel-Lindau disease refers to any of the benign or malignant tumors and cysts that arise in patients with von Hippel-Lindau disease, a rare autosomal dominant hereditary cancer predisposition syndrome.

It predominantly affects adults and young adults across multiple organ systems, most commonly manifesting as central nervous system and retinal hemangioblastomas, clear cell renal cell carcinomas, pancreatic neuroendocrine tumors, and pheochromocytomas.

Pathophysiologically, germline inactivation of the VHL tumor suppressor gene impairs the degradation of hypoxia-inducible factors, notably HIF-2a, leading to constitutive pseudohypoxic signaling, overexpression of angiogenic growth factors, and hypervascular neoplastic growth.

Clinically, these neoplasms are characteristically multifocal, bilateral, and recurrent, often requiring specialized systemic management or nephron- and organ-sparing interventions.

Personalize your experience

Follow Neoplasm associated with von Hippel-Lindau disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it